EcoDrugPlus

Mitogen-Activated Protein Kinase Kinase Kinase 11

Ensembl ID : ENSMPUG00000011832
Gene Symbol: MAP3K11
2 Cross references
183 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 12

Ensembl ID : ENSMPUG00000005953
Gene Symbol: MAP3K12
2 Cross references
254 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 13

Ensembl ID : ENSMPUG00000003062
Gene Symbol: MAP3K13
2 Cross references
198 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 5

Ensembl ID : ENSMPUG00000014837
Gene Symbol: MAP3K5
2 Cross references
203 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 8

Ensembl ID : ENSMPUG00000016415
Gene Symbol: MAP3K8
2 Cross references
198 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 9

Ensembl ID : ENSMPUG00000003616
Gene Symbol: MAP3K9
2 Cross references
194 Possible Orthologues:

Monoamine Oxidase A

Ensembl ID : ENSMPUG00000012650
Gene Symbol: MAOA
2 Cross references
146 Possible Orthologues:

Monoamine Oxidase B

Ensembl ID : ENSMPUG00000012731
Gene Symbol: MAOB
2 Cross references
328 Possible Orthologues:

Monoglyceride Lipase

Ensembl ID : ENSMPUG00000017344
Gene Symbol: MGLL
2 Cross references
208 Possible Orthologues:

Motilin Receptor

Ensembl ID : ENSMPUG00000018022
Gene Symbol: MLNR
2 Cross references
165 Possible Orthologues:

Myeloperoxidase

Ensembl ID : ENSMPUG00000015340
Gene Symbol: MPO
2 Cross references
181 Possible Orthologues:

Natriuretic Peptide Receptor 1

Ensembl ID : ENSMPUG00000008249
Gene Symbol: NPR1
2 Cross references
184 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).